Sangui Biotech International (SGBI) 10-Q 13 Feb 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Dec. 31, 2019	Feb. 13, 2020
Details
Registrant CIK	0001104280
Fiscal Year End	--06-30
Registrant Name	SANGUI BIOTECH INTERNATIONAL INC
SEC Form	10-Q
Period End date	Dec. 31, 2019
Tax Identification Number (TIN)	84-1330732
Number of common stock shares outstanding		202,729,842
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Document Quarterly Report	true
Entity File Number	0-21271
Entity Address, State or Province	CO
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	Neuer Wall 54
Entity Address, Postal Zip Code	20354
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Country Region	49
City Area Code	40
Local Phone Number	46093120
Document Transition Report	false
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Jun. 30, 2019
CURRENT ASSETS
Cash	$ 15,395	$ 27,453
Prepaid expenses and other assets	16,583	9,470
Tax refunds receivable	5,517	6,852
Accounts receivable, net	14,508	29,525
Note receivable, related party	985	5,671
Total Current Assets	52,988	78,971
Operating lease right-of-use asset	3,002	0
TOTAL ASSETS	55,990	78,971
CURRENT LIABILITIES
Accounts payable and accrued expenses	125,435	164,145
Accrued interest - related party	34,783	28,458
Notes payable - related party	538,358	478,357
Operating lease liability	3,002	0
Total Current Liabilities	701,578	670,960
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 201,533,598 and 199,295,503 shares issued and 201,479,842 and 199,241,747 shares outstanding respectively	33,012,261	32,967,499
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	92,212	91,447
Accumulated deficit	(37,600,416)	(37,503,684)
Total Sangui Biotech International, Inc's stockholders' equity (defict)	(2,002)	49,203
Non-controlling interest	(643,586)	(641,192)
Total Stockholders' Deficit	(645,588)	(591,989)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 55,990	$ 78,971

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - shares	Dec. 31, 2019	Jun. 30, 2019
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	201,533,598	199,295,503
Common Stock, Shares, Outstanding	201,479,842	199,241,747

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
REVENUES
License revenues	$ 11,683	$ 44,095	$ 11,965	$ 55,367
COST OF SALES	0	26	0	99
GROSS MARGIN	11,683	44,069	11,965	55,268
OPERATING EXPENSES
Research and development	2,650	7,314	4,886	15,286
Professional fees	37,666	53,282	79,418	103,216
General and administrative	7,900	43,610	20,092	90,401
Total Operating Expenses	48,216	104,206	104,396	208,903
OPERATING LOSS	(36,533)	(60,137)	(92,431)	(153,635)
OTHER INCOME (EXPENSE)
Loss on out of court settlement	0	0	(6,714)	0
Gain (loss) on foreign exchange	(15,111)	5,395	6,709	6,457
Interest expense	(3,477)	(2,525)	(6,690)	(6,216)
Total other income (expense)	(18,588)	2,870	(6,695)	241
LOSS BEFORE INCOME TAXESAND NON-CONTROLLING INTEREST	(55,121)	(57,267)	(99,126)	(153,394)
Provision for income taxes	0	1,213	0	1,213
NET LOSS BEFORE NON-CONTROLLING INTEREST	(55,121)	(58,480)	(99,126)	(154,607)
Less: Net loss attributable to non-controlling interest	1,138	2,124	2,394	8,288
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(53,983)	(56,356)	(96,732)	(146,319)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(2,255)	(1,721)	765	(1,336)
COMPREHENSIVE LOSS	$ (57,376)	$ (60,201)	$ (98,361)	$ (155,943)
BASIC AND DILUTED LOSS PER SHARE	$ 0	$ 0	$ 0	$ 0
BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	201,533,598	195,147,849	200,819,827	195,007,308

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Treasury Stock	AOCI Including Portion Attributable to Noncontrolling Interest	Noncontrolling Interest	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2018	$ 32,864,356	$ 4,513,328	$ (19,387)	$ 92,921	$ (622,254)	$ (37,180,108)	$ (351,144)
Shares, Outstanding, Beginning Balance at Jun. 30, 2018	191,951,503
Common shares issued for Cash	$ 84,491	0	0	0	0	0	84,491
Stock Issued During Period, Shares, New Issues	6,500,000
Common stock issued for services	$ 18,652	0	0	0	0	0	18,652
Stock Issued During Period, Shares, Issued for Services	844,000
Currency translation adjustment	$ 0	0	0	(1,336)	0	0	(1,336)
Net loss	0	0	0	0	(8,288)	(146,319)	(154,607)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2018	$ 32,967,499	4,513,328	(19,387)	91,585	(630,542)	(37,326,427)	(403,944)
Shares, Outstanding, Ending Balance at Dec. 31, 2018	199,295,503
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Sep. 30, 2018	$ 32,884,893	4,513,328	(19,387)	93,306	(628,418)	(37,270,071)	(426,349)
Shares, Outstanding, Beginning Balance at Sep. 30, 2018	192,951,503
Common shares issued for Cash	$ 63,954	0	0	0	0	0	63,954
Stock Issued During Period, Shares, New Issues	5,500,000
Common stock issued for services	$ 18,652	0	0	0	0	0	18,652
Stock Issued During Period, Shares, Issued for Services	844,000
Currency translation adjustment	$ 0	0	0	(1,721)	0	0	(1,721)
Net loss	0	0	0	0	(2,124)	(56,356)	(58,480)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2018	$ 32,967,499	4,513,328	(19,387)	91,585	(630,542)	(37,326,427)	(403,944)
Shares, Outstanding, Ending Balance at Dec. 31, 2018	199,295,503
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2019	$ 32,967,499	4,513,328	(19,387)	91,447	(641,192)	(37,503,684)	(591,989)
Shares, Outstanding, Beginning Balance at Jun. 30, 2019	199,295,503
Common stock issued for services	$ 44,762	0	0	0	0	0	$ 44,762
Stock Issued During Period, Shares, Issued for Services	2,238,095						2,238,095
Currency translation adjustment	$ 0	0	0	765	0	0	$ 765
Net loss	0	0	0	0	(2,394)	(96,732)	(99,126)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2019	$ 33,012,261	4,513,328	(19,387)	92,212	(643,586)	(37,600,416)	(645,588)
Shares, Outstanding, Ending Balance at Dec. 31, 2019	201,533,598
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Sep. 30, 2019	$ 33,012,261	4,513,328	(19,387)	94,467	(642,448)	(37,546,433)	(588,212)
Shares, Outstanding, Beginning Balance at Sep. 30, 2019	201,533,598
Currency translation adjustment	$ 0	0	0	(2,255)	0	0	(2,255)
Net loss	0	0	0	0	(1,138)	(53,982)	(55,121)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2019	$ 33,012,261	$ 4,513,328	$ (19,387)	$ 92,212	$ (643,586)	$ (37,600,416)	$ (645,588)
Shares, Outstanding, Ending Balance at Dec. 31, 2019	201,533,598

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (99,126)	$ (154,607)
Adjustments to reconcile net loss to net cash used by operating activities:
Common stock issued for services	0	18,652
Common stock issued for obtaining out-of-court settlement	6,714	0
Foreign currency exchange transactions	(6,709)	(6,457)
Amortization of right to use asset	(3,532)	0
Changes in operating assets and liabilities
Trade accounts receivable	14,418	(5,211)
Prepaid expenses and other current assets	(11,781)	747
Tax refunds receivable	1,002	(5,735)
Accounts payable and accrued expenses	4,386	(2,700)
Related party advances	5,527	6,160
Related party accounts payable	6,693	3,948
Operationg lease liability	3,532	0
Net Cash Used in Operating Activities	(78,876)	(145,203)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party note payable	66,342	720,341
Repayment of related party note payable	0	(604,756)
Proceeds from common stock issued for cash	0	84,491
Repayment of notes payable	0	(37,971)
Net Cash Provided by Financing Activities	66,342	162,105
EFFECTS OF EXCHANGE RATES ON CASH	476	(1,602)
NET CHANGES IN CASH	(12,058)	15,300
CASH AT BEGINNING OF PERIOD	27,453	20,943
CASH AT END OF PERIOD	15,395	36,243
CASH FLOW INFORMATION
Interest	0	2,509
Income Taxes	0	0
NON - CASH INVESTING AND FINANCING ACTIVITIES
Right of use operating lease assets obtained in exchange for lease liabilities	6,504	0
Stock issued in settlement of liability	$ 44,762	$ 0

NOTE 1 - BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION	6 Months Ended
	Dec. 31, 2019
Notes
NOTE 1 - BASIS OF PRESENTATION	NOTE 1 - BASIS OF PRESENTATION The accompanying condensed consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2019. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three - and six-month period ended December 31, 2019 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2020.

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2019
Notes
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its 90% owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Hamburg, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Sangui KG is a limited partnership that holds the license rights under the various agreements that the Company enters into from time to time. Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of December 31, 2019 and June 30, 2019 and our unaudited consolidated statements of operations for the three - and six-month periods ended December 31, 2019 and 2018, were calculated as follows: The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other income. as of December 31, 2019 0.891600 as of December 31, 2018 0.874245 July 1, 2019 through December 31, 2019 0.900817 July 1, 2018 through December 31, 2018 0.868118 Risk and Uncertainties The Company's line of future pharmaceutical products (artificial oxygen carriers or blood substitute and additives) and medical products (wound dressings and other wound management products) being developed by Sangui GmbH, are deemed as medical devices or biologics, and as such are governed by the Federal Food and Drug and Cosmetics Act and by the regulations of state agencies and various foreign government agencies. The pharmaceuticals, under development in Germany, will be subject to more stringent regulatory requirements, because they are in vivo products for humans. The Company and its subsidiaries have no experience in obtaining regulatory clearance on these types of products. Therefore, the Company will be subject to the risks of delays in obtaining or failing to obtain regulatory clearance. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $ 37,600,416 99,126 78,876 Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts. Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred. Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied. Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of December 31, 2019, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive. Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit). Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 3 - COMMITMENTS AND CONTIN

NOTE 3 - COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Dec. 31, 2019
Notes
NOTE 3 - COMMITMENTS AND CONTINGENCIES	NOTE 3 - COMMITMENTS AND CONTINGENCIES Litigation The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a material effect on the Company's financial position or results of operations. At the time of reporting, no litigations are pending. Indemnities and Guarantees During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet. Leases Effective from June 30, 2019 the Company has closed the site in Witten and relocated its headquarters to Hamburg. The Company leases office facilities from an unrelated third party at 685 Euros per month. The office lease contract is maintained on a month-to-month basis. The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month beginning June 2018 expiring May 2020. The following table reconciles future minimum operating lease payments to the discounted lease liability as of June 30, 2019: Minimum Lease Payments Under Operating Leases 2020 $ 3,017 Total Operating Lease Obligations $ 3,017 Less: Amount representing imputed interest $ (15) Present Value of minimum lease payments $ 3,002 Weighted average discount rate 2% License Agreement Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH respectively Sangui KG and a former contractor, Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG).

NOTE 4 - DEBT

NOTE 4 - DEBT	6 Months Ended
	Dec. 31, 2019
Notes
NOTE 4 - DEBT	NOTE 4 – DEBT Notes Payable Related Parties As of December 31, 2019, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 112,158 5% 26,052 June 30, 2020 December 12, 2017 25,000 28,039 2% 1,151 on demand January 19, 2018 25,000 28,039 2% 1,092 on demand March 13, 2018 25,000 28,039 2% 1,011 on demand July 16, 2018 25,000 28,039 2% 819 on demand September 10, 2018 25,000 28,039 2% 733 on demand October 04, 2018 25,000 28,039 2% 696 on demand December 27, 2018 25,000 28,039 2% 567 on demand January 21, 2019 15,000 16,824 2% 317 on demand February 26, 2019 25,000 28,039 2% 473 on demand March 20, 2019 25,000 28,039 2% 439 on demand April 08, 2019 20,000 22,432 2% 328 on demand May 09, 2019 30,000 33,647 2% 435 on demand June 21, 2019 30,000 33,647 2% 356 on demand September 17, 2019 20,000 22,432 2% 129 on demand October 04, 2019 20,000 22,432 2% 108 on demand October 30, 2019 20,000 22,432 2% 76 on demand On September 17, 209, on October 04, 2019 and on October 30, 2019 a Company Director advanced amount of 20,000 Euros ($ 22,432 313

NOTE 5 - CAPITAL STOCK

NOTE 5 - CAPITAL STOCK	6 Months Ended
	Dec. 31, 2019
Notes
NOTE 5 - CAPITAL STOCK	NOTE 5 – CAPITAL STOCK Preferred Stock Common Stock 201,533,598 199,295,503 201,479,842 199,241,747 During the six months ended December 31, 2019, the Company issued 2,238,095 44,762 0.0200 38,048 6,714 Treasury Stock 53,756 19,387 Stock – Based Compensation

NOTE 6 - SUBSEQUENT EVENTS

NOTE 6 - SUBSEQUENT EVENTS	6 Months Ended
	Dec. 31, 2019
Notes
NOTE 6 - SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS Subsequent to December 31, 2019, a Company Director advanced 10,000 11,216 Subsequent to December 31, 2019, the Company sold 1,250,000 11,055 0.009 In accordance with ASC 855-10, the Company’s management has reviewed all material events and there are no additional material subsequent events to report.

NOTE 2 - SUMMARY OF SIGNIFICA_2

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2019
Policies
Consolidation	Consolidation The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Foreign Currency Translation	Foreign Currency Translation Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period. Exchanges rates used for the preparation of the consolidated balance sheet as of December 31, 2019 and June 30, 2019 and our unaudited consolidated statements of operations for the three - and six-month periods ended December 31, 2019 and 2018, were calculated as follows: The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other income. as of December 31, 2019 0.891600 as of December 31, 2018 0.874245 July 1, 2019 through December 31, 2019 0.900817 July 1, 2018 through December 31, 2018 0.868118
Risks and Uncertainties	Risk and Uncertainties The Company's line of future pharmaceutical products (artificial oxygen carriers or blood substitute and additives) and medical products (wound dressings and other wound management products) being developed by Sangui GmbH, are deemed as medical devices or biologics, and as such are governed by the Federal Food and Drug and Cosmetics Act and by the regulations of state agencies and various foreign government agencies. The pharmaceuticals, under development in Germany, will be subject to more stringent regulatory requirements, because they are in vivo products for humans. The Company and its subsidiaries have no experience in obtaining regulatory clearance on these types of products. Therefore, the Company will be subject to the risks of delays in obtaining or failing to obtain regulatory clearance.
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $ 37,600,416 99,126 78,876
Cash and Cash Equivalents	Cash and Cash Equivalents The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.
Research and Development	Research and Development Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Type of Revenue The Company derives revenue primarily from licensing fees on sales of its wound spray product. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below. The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied.
Basic and Diluted Loss per Common Share	Basic and Diluted Earnings (Loss) Per Common Share Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of December 31, 2019, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.
Comprehensive Loss	Comprehensive Loss Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).
Segments of an Enterprise and Related Information	Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity. Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

NOTE 2 - SUMMARY OF SIGNIFICA_3

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Foreign currency rates	The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other income. as of December 31, 2019 0.891600 as of December 31, 2018 0.874245 July 1, 2019 through December 31, 2019 0.900817 July 1, 2018 through December 31, 2018 0.868118

NOTE 3 - COMMITMENTS AND CONT_2

NOTE 3 - COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Dec. 31, 2019
Tables/Schedules
Minimum Lease Payments Under Operating Leases	The following table reconciles future minimum operating lease payments to the discounted lease liability as of June 30, 2019: Minimum Lease Payments Under Operating Leases 2020 $ 3,017 Total Operating Lease Obligations $ 3,017 Less: Amount representing imputed interest $ (15) Present Value of minimum lease payments $ 3,002 Weighted average discount rate 2%

NOTE 4 - DEBT (Tables)

NOTE 4 - DEBT (Tables)	6 Months Ended
	Dec. 31, 2019
Tables/Schedules
Notes Payable Related Parties	As of December 31, 2019, the Company had outstanding the following loans payable due to a Company Director: Date Loan amount in EURO Loan amount converted into USD Interest rate Interest in USD Due March 06, 2015 100,000 112,158 5% 26,052 June 30, 2020 December 12, 2017 25,000 28,039 2% 1,151 on demand January 19, 2018 25,000 28,039 2% 1,092 on demand March 13, 2018 25,000 28,039 2% 1,011 on demand July 16, 2018 25,000 28,039 2% 819 on demand September 10, 2018 25,000 28,039 2% 733 on demand October 04, 2018 25,000 28,039 2% 696 on demand December 27, 2018 25,000 28,039 2% 567 on demand January 21, 2019 15,000 16,824 2% 317 on demand February 26, 2019 25,000 28,039 2% 473 on demand March 20, 2019 25,000 28,039 2% 439 on demand April 08, 2019 20,000 22,432 2% 328 on demand May 09, 2019 30,000 33,647 2% 435 on demand June 21, 2019 30,000 33,647 2% 356 on demand September 17, 2019 20,000 22,432 2% 129 on demand October 04, 2019 20,000 22,432 2% 108 on demand October 30, 2019 20,000 22,432 2% 76 on demand

NOTE 2 - SUMMARY OF SIGNIFICA_4

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Dec. 31, 2019
Sangui BioTech GmbH
Equity Method Investment, Ownership Percentage	90.00%

NOTE 2 - SUMMARY OF SIGNIFICA_5

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Details)	Dec. 31, 2019	Dec. 31, 2018
Year End Rates
Foreign Currency Exchange Rate, Translation	0.891600	0.874245
Average Period Rates
Foreign Currency Exchange Rate, Translation	0.900817	0.868118

NOTE 2 - SUMMARY OF SIGNIFICA_6

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019
Details
Accumulated deficit	$ 37,600,416		$ 37,600,416		$ 37,503,684
NET LOSS BEFORE NON-CONTROLLING INTEREST	$ 55,121	$ 58,480	99,126	$ 154,607
Net Cash Used in Operating Activities			$ 78,876	$ 145,203

NOTE 3 - COMMITMENTS AND CONT_3

NOTE 3 - COMMITMENTS AND CONTINGENCIES (Details)	6 Months Ended
	Dec. 31, 2019
Office
Lessee, Operating Lease, Description	The Company leases office facilities from an unrelated third party at 685 Euros per month. The office lease contract is maintained on a month-to-month basis.
Automobile
Lessee, Operating Lease, Description	The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month beginning June 2018 expiring May 2020.

NOTE 3 - COMMITMENTS AND CONT_4

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Details
Operating Leases, Future Minimum Payments Due, Next Twelve Months		$ 3,017
Operating Leases, Future Minimum Payments Due	$ 3,017
Operating Leases, Rent Expense	(15)
Operating Lease, Liability	$ 3,002
Lessee, Operating Lease, Discount Rate		2.00%

NOTE 4 - DEBT_ Notes Payable Re

NOTE 4 - DEBT: Notes Payable Related Parties (Details) - USD ($)	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015	Dec. 31, 2019
Interest rate	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Due	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	June 30, 2020
Director
Interest rate																		2.00%
Director | Euro Member Countries, Euro
Loan amount in EURO	$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 20,000	$ 25,000	$ 25,000	$ 15,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 100,000
Director | United States dollar (next day) (funds code)
Loan amount converted into USD	22,432	22,432	22,432	33,647	33,647	22,432	28,039	28,039	16,824	28,039	28,039	28,039	28,039	28,039	28,039	28,039	112,158
Interest in USD	$ 76	$ 108	$ 129	$ 356	$ 435	$ 328	$ 439	$ 473	$ 317	$ 567	$ 696	$ 733	$ 819	$ 1,011	$ 1,092	$ 1,151	$ 26,052

NOTE 4 - DEBT (Details)

NOTE 4 - DEBT (Details) - USD ($)	Dec. 31, 2019	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 30, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Accrued interest - related party	$ 34,783				$ 28,458
Interest rate		2.00%	2.00%	2.00%		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Director
Interest rate	2.00%
Director | Principal
Accrued interest - related party	$ 22,432
Director | Interest
Accrued interest - related party	$ 313

NOTE 5 - CAPITAL STOCK (Details

NOTE 5 - CAPITAL STOCK (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2018	Jun. 30, 2019
Preferred Stock, Shares Authorized	10,000,000		10,000,000			10,000,000
Common Stock, Shares Authorized	250,000,000		250,000,000			250,000,000
Common Stock, Shares, Issued	201,533,598		201,533,598			199,295,503
Common Stock, Shares, Outstanding	201,479,842		201,479,842			199,241,747
Stock Issued During Period, Shares, Issued for Services			2,238,095
Common stock issued for services		$ 18,652	$ 44,762	$ 18,652	$ 38,048
LossOnOutOfCourtSettlement	$ 0	$ 0	$ 6,714	$ 0
Treasury Stock, Common, Shares	53,756		53,756
Treasury Stock, Value	$ 19,387		$ 19,387
2008 Amended And Restated Long Term Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award, Description			the Board was authorized to issue up to 10,000,000 shares of common stock (including incentive stock options) to certain eligible employees, directors, and consultants of the Company or its subsidiaries. The term of the plan was 10 years. It expired in October 2018.

NOTE 6 - SUBSEQUENT EVENTS (Det

NOTE 6 - SUBSEQUENT EVENTS (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2020	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2018	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Proceeds from related party note payable			$ 66,342	$ 720,341
Interest rate						2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Stock Issued During Period, Shares, Issued for Services			2,238,095
Common stock issued for services		$ 18,652	$ 44,762	$ 18,652	$ 38,048
Common Stock
Stock Issued During Period, Shares, Issued for Services		844,000	2,238,095	844,000
Common stock issued for services		$ 18,652	$ 44,762	$ 18,652
Subsequent Event
Common stock issued for services	$ 11,055
Subsequent Event | Common Stock
Stock Issued During Period, Shares, Issued for Services	1,250,000
Shares Issued, Price Per Share	$ 0.009
Director
Interest rate			2.00%
Director | Subsequent Event
Proceeds from related party note payable	$ 11,216
Interest rate	2.00%